Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...
6d
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback